Lansoprazole
Brand names: Lansoprazole, Prevacid
At a glance
- Medicare prescriptions, 2024
- 740,818
- Medicare drug cost
- $28.0M
- Average cost per prescription
- $37.82
- Clinicians who prescribed it
- 33,262
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
PREVACID and PREVACID SoluTab are proton pump inhibitors (PPIs) indicated for the: Treatment of active duodenal ulcer in adults. Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults. Maintenance of healed duodenal ulcers in adults. Treatment of active benign gastric ulcer in adults. Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults. Risk reduction of NSAID-associated gastric ulcer in adults. Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older. Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. Maintenance of healing of EE in adults. Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES) in adults.
From the FDA-approved prescribing information (label dated July 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 31.0%
- Internal Medicine 27.6%
- Nurse Practitioners 13.1%
- Gastroenterology 11.7%
- Physician Assistants 6.1%
- General Practice 4.2%
- Geriatric Medicine 1.5%
- Cardiology 0.6%
- ENT (Otolaryngology) 0.5%
- Hospitalist 0.4%
- Pulmonology 0.3%
- General Surgery 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 18% from 2019 to 2024.
Biggest change by state since 2019
- Mississippi +69%
- Utah +67%
- Arizona +42%
- Iowa +40%
- Kansas +39%
- West Virginia (smallest change) −3%
- Michigan (smallest change) −2%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Cardinal Health 107, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 30 mg | white round tablet, 12 mm | J 72 |
Lifestar Pharma LLC.
| Strength | Looks like | Imprint |
|---|---|---|
| 15 mg | white capsule, 16 mm | 806 |
| 30 mg | white capsule, 19 mm | 807 |
Nucare Pharmaceuticals,inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 15 mg | white capsule, 16 mm | 806 |
Safecor Health LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 30 mg | pink capsule, 21 mm | MYLAN 8030 |
Takeda Pharmaceuticals America, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 15 mg | white round tablet, 9 mm | 15 |
| 30 mg | black capsule, 19 mm | TAP PREVACID 30 |
| 30 mg | white round tablet, 12 mm | 30 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
3 recalls since 2020
- Mar 2022 · Dr. Reddy's Laboratories, Inc. · Class II
Failed Dissolution Specifications; during long term stability testing. - Dec 2020 · Zydus Pharmaceuticals (USA) Inc · Class II
Failed Dissolution Specifications - Oct 2020 · Zydus Pharmaceuticals (USA) Inc · Class II
Failed Dissolution Specification
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.